Alector stock plummets 13% as GSK terminates neuroscience pact
Seeking Alpha ·
Alector ( ALEC ) Wednesday said that GSK had terminated their neuroscience collaboration deal covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks. Alector ( ALEC ) shares dropped 13% in extended trading, GSK eased 1.5%.
DYAX Investor Sentiment
Bullish (Long) 73% · Bearish (Short) 27%
380 participants
Related News
- Aimei Health drops 30% after terminating United Hydrogen merger deal
- Nocera drops 8% after 7.5M share resale filing
- Keeper Security surpasses $225M in ARR with transformative growth and is emerging as the market standard for AI-native identity security
- Sempra’s ECA LNG phase 1 ships first cargo from Mexico
- Here's When Elon Musk Can Sell His Billions of SpaceX Shares
- Micron Raised Its Guidance on Surging Memory Prices. Here's What It Means for the Stock.